Mittal Rathod
Research Subjects
Mittal Rathod has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Mehul Kaliya
All India Institute of Medical Sciences
2 shared publications - Harsha M. Solanki
Community Medicine Department, P D U Govt. Medical College, Rajkot, Gujarat, India
1 shared publication - K. S. Aviraj
Department of Community Medicine, ESIC Medical College and Hospital, Noida, Uttar Pradesh, India
1 shared publication - Renu Agrawal
Sarojini Naidu Medical College, Agra, Uttar Pradesh
1 shared publication - Subba Krishna Nagaraj
Department of Community Medicine, BGS MCH Hospital, Bengaluru, Karnataka, India
1 shared publication
Latest Publications
- 19 November 2026
- Published by Wolters Kluwer Health in Preventive Medicine: Research & Reviews
Public Health in the Digital Era: A Narrative Review of Technology-driven Interventions and Programmatic Advances in India
Digital technologies are increasingly integral to public health systems, offering opportunities to improve disease surveillance, service delivery, efficiency and equity. In India, multiple government-led digital platforms have been implemented across public health programmes; however, consolidated evidence on their scope, effectiveness and implementation challenges remains limited. The manuscript was prepared in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) guidelines. This narrative review aimed to examine technology-driven public health interventions implemented in India, focusing on government-supported digital platforms excluding artificial intelligence-based tools, and summarised their applications, achievements and limitations. A narrative review using a structured search strategy was conducted across PubMed, Google Scholar, Scopus, ResearchGate and official portals of the Ministry of Health and Family Welfare, National Health Mission and WHO-SEARO. English-language literature published between January 2005 and June 2025 was included. Eligible source findings were thematically synthesised across major public health domains. Thirty-five eligible studies and national programme documents were included. Digital platforms such as Integrated Disease Surveillance Programme and Integrated Health Information Platform strengthened disease surveillance through real-time reporting and outbreak analytics. Maternal and child health tools (Mother and Child Tracking System, ANMOL, and Kilkari) improved beneficiary tracking, antenatal follow-up and health education. Immunisation systems (Electronic Vaccine Intelligence Network, CoWIN/U-WIN) enhanced vaccine logistics and coverage. Platforms for non-communicable diseases and telemedicine supported continuity of care and expanded access to specialist services. Key challenges included digital literacy gaps, connectivity constraints, interoperability issues, workforce burden and data governance concerns. Digital platforms have strengthened specific public health functions in India, but have not achieved uniform system-wide transformation. Addressing interoperability, evaluation frameworks, equity and governance is essential to maximise their public health impact.
- 19 November 2026
- Published by Wolters Kluwer Health in Preventive Medicine: Research & Reviews
Public Health in the Digital Era: A Narrative Review of Technology-driven Interventions and Programmatic Advances in India
Digital technologies are increasingly integral to public health systems, offering opportunities to improve disease surveillance, service delivery, efficiency and equity. In India, multiple government-led digital platforms have been implemented across public health programmes; however, consolidated evidence on their scope, effectiveness and implementation challenges remains limited. The manuscript was prepared in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) guidelines. This narrative review aimed to examine technology-driven public health interventions implemented in India, focusing on government-supported digital platforms excluding artificial intelligence-based tools, and summarised their applications, achievements and limitations. A narrative review using a structured search strategy was conducted across PubMed, Google Scholar, Scopus, ResearchGate and official portals of the Ministry of Health and Family Welfare, National Health Mission and WHO-SEARO. English-language literature published between January 2005 and June 2025 was included. Eligible source findings were thematically synthesised across major public health domains. Thirty-five eligible studies and national programme documents were included. Digital platforms such as Integrated Disease Surveillance Programme and Integrated Health Information Platform strengthened disease surveillance through real-time reporting and outbreak analytics. Maternal and child health tools (Mother and Child Tracking System, ANMOL, and Kilkari) improved beneficiary tracking, antenatal follow-up and health education. Immunisation systems (Electronic Vaccine Intelligence Network, CoWIN/U-WIN) enhanced vaccine logistics and coverage. Platforms for non-communicable diseases and telemedicine supported continuity of care and expanded access to specialist services. Key challenges included digital literacy gaps, connectivity constraints, interoperability issues, workforce burden and data governance concerns. Digital platforms have strengthened specific public health functions in India, but have not achieved uniform system-wide transformation. Addressing interoperability, evaluation frameworks, equity and governance is essential to maximise their public health impact.
- Open Access
- 16 March 2026
- Published by Wolters Kluwer Health in Preventive Medicine: Research & Reviews
- Vol. 3 (5) , 299-306
Financial Burden of Drug-sensitive Tuberculosis in India: A Systematic Review and Meta-analysis
Introduction: Tuberculosis (TB) poses a significant public health and economic burden in India, with out-of-pocket expenditure (OOPE) often leading to financial distress. This study reviews and meta-analyses costs associated with drug-sensitive TB care in India. Methods: Relevant studies from PubMed, Scopus, OpenAlex, CrossRef and Semantic Scholar were analysed. A random-effects meta-analysis estimated mean costs, including direct medical, direct non-medical, indirect medical, diagnostic and treatment expenses. Results: Analysing 18 studies, the overall mean cost per TB patient was ₹18,961 (95% confidence interval: ₹12,093–₹25,829), with direct medical costs at ₹7305, direct non-medical costs at ₹2346, indirect medical costs at ₹10,602, diagnostic costs at ₹10,028 and treatment costs at ₹12,999. Conclusion: TB care imposes a heavy financial burden on Indian households. Reducing OOPE through targeted interventions, strengthened social protection and expanded free services is essential to alleviate this hardship.
- 16 March 2026
- Published by Wolters Kluwer Health in Preventive Medicine: Research & Reviews
- Vol. 3 (5) , 299-306
Open AccessFinancial Burden of Drug-sensitive Tuberculosis in India: A Systematic Review and Meta-analysis
Introduction: Tuberculosis (TB) poses a significant public health and economic burden in India, with out-of-pocket expenditure (OOPE) often leading to financial distress. This study reviews and meta-analyses costs associated with drug-sensitive TB care in India. Methods: Relevant studies from PubMed, Scopus, OpenAlex, CrossRef and Semantic Scholar were analysed. A random-effects meta-analysis estimated mean costs, including direct medical, direct non-medical, indirect medical, diagnostic and treatment expenses. Results: Analysing 18 studies, the overall mean cost per TB patient was ₹18,961 (95% confidence interval: ₹12,093–₹25,829), with direct medical costs at ₹7305, direct non-medical costs at ₹2346, indirect medical costs at ₹10,602, diagnostic costs at ₹10,028 and treatment costs at ₹12,999. Conclusion: TB care imposes a heavy financial burden on Indian households. Reducing OOPE through targeted interventions, strengthened social protection and expanded free services is essential to alleviate this hardship.
- Open Access
- 30 September 2025
- Published by Indian Association of Preventive and Social Medicine - Gujarat Chapter in Healthline
- Vol. 16 (3) , 240-242
From 99DOTS to 99DOTSLite in Gujarat: A Pragmatic Leap in TB Treatment Adherence
In 2013, Microsoft Research India launched a digital adherence technology (DAT) called 99DOTS which was created to overcome low treatment adherence in India's tuberculosis (TB) program. It employed the use of envelope-based medication delivery with concealed numbers which were unlocked and dialed by the patient to record compliance. Although successful in small-scale pilots, widespread adoption revealed several weaknesses such as dependence on packaging, complexity, and imprecision. To address these, the Central TB Division introduced a simplified version of its system, 99DOTSLite, in 2023, which relies on district-specific toll-free numbers (TFNs) printed on the medication packs or ID cards. Patients verify intake by making a missed call which gets automatically registered in Ni-kshay and thus followed up in real time in case of missed doses. In comparison to the previous systems, 99DOTSLite is affordable, compatible with any TB regimen, user-friendly, and easily integrated with the digital TB environment of India. Even though issues with phone access, connection, and possible false reporting are possible, 99DOTSLite is an open-ended, patient-centered innovation essential to India TB elimination activities.
- 30 September 2025
- Published by Indian Association of Preventive and Social Medicine - Gujarat Chapter in Healthline
- Vol. 16 (3) , 240-242
Open AccessFrom 99DOTS to 99DOTSLite in Gujarat: A Pragmatic Leap in TB Treatment Adherence
In 2013, Microsoft Research India launched a digital adherence technology (DAT) called 99DOTS which was created to overcome low treatment adherence in India's tuberculosis (TB) program. It employed the use of envelope-based medication delivery with concealed numbers which were unlocked and dialed by the patient to record compliance. Although successful in small-scale pilots, widespread adoption revealed several weaknesses such as dependence on packaging, complexity, and imprecision. To address these, the Central TB Division introduced a simplified version of its system, 99DOTSLite, in 2023, which relies on district-specific toll-free numbers (TFNs) printed on the medication packs or ID cards. Patients verify intake by making a missed call which gets automatically registered in Ni-kshay and thus followed up in real time in case of missed doses. In comparison to the previous systems, 99DOTSLite is affordable, compatible with any TB regimen, user-friendly, and easily integrated with the digital TB environment of India. Even though issues with phone access, connection, and possible false reporting are possible, 99DOTSLite is an open-ended, patient-centered innovation essential to India TB elimination activities.